Viral Vector And Plasmid Dna Manufacturing Market Scope And Analysis

Report Code : TIPRE00003074
Category : Biotechnology

Status : Published
No. of Pages : 140

Buy Now

Viral Vector and Plasmid DNA Manufacturing Market Scope and Analysis by 2027

Buy Now

Viral Vector and Plasmid DNA Manufacturing Market Report Scope

Report Attribute	Details
Market size in 2019	US$ 459.4 Million
Market Size by 2027	US$ 2,247.7 Million
Global CAGR (2019 - 2027)	22.1%
Historical Data	2017-2018
Forecast period	2020-2027
Segments Covered	By Product Viral Vectors and Non-viral Vectors By Application Cancer Inherited Disorders Viral Infections
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Brammer Bio Sanofi FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy Catapult Cobra Biologics FinVector Kaneka Eurogentec S A MassBiologics Spark Therapeutics

Recent Developments:

Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the viral vector and plasmid DNA manufacturing market. A few recent key market developments are listed below:

In March 2023, Sartorius acquired French company Polyplus for 2.4 billion euros ($2.6 billion). The deal gives Sartorius additional know-how in nucleic acid delivery, including transfection reagents and plasmid DNA design, all of which are key elements in the production of viral vectors for building cell and gene therapies.
In July 2021, Thermo Fisher Scientific Inc. opened a new cGMP plasmid DNA manufacturing facility in Carlsbad, Calif., enabling it to meet rapidly growing demand for plasmid DNA-based therapies and vital mRNA-based vaccines.
In March 2021, WACKER acquired 100% of the shares in pharmaceutical contract manufacturer Genopis Inc. from Helixmith Co Ltd, Seoul (South Korea) and Medivate Partners LLC, Seoul (South Korea) in February. The signing of the related agreement was followed by the successful closing in late February and, now, the acquisition’s new name: Wacker Biotech US Inc.